CY1120591T1 - Ιατρικη συνθεση για βελτιωση λειτουργιας εγκεφαλου - Google Patents
Ιατρικη συνθεση για βελτιωση λειτουργιας εγκεφαλουInfo
- Publication number
- CY1120591T1 CY1120591T1 CY181100871T CY181100871T CY1120591T1 CY 1120591 T1 CY1120591 T1 CY 1120591T1 CY 181100871 T CY181100871 T CY 181100871T CY 181100871 T CY181100871 T CY 181100871T CY 1120591 T1 CY1120591 T1 CY 1120591T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cerebral
- ingredient
- integer
- optionally substituted
- hydroxyl group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Χρήση των παρακάτω συστατικών σε συνδυασμό για χρήση στη θεραπεία ή την αποτροπή δυσλειτουργίας εγκεφαλικών νευρώνων ακετυλοχολίνης στα επακόλουθα εγκεφαλοαγγειακής άνοιας, γεροντικής άνοιας, ασθένειας Alzheimer, ισχαιμικής εγκεφαλικής βλάβης και εγκεφαλικής αποπληξίας ή την εξασθένηση μνήμης που προκαλείται με εκλεκτικό νευρωνικό θάνατο:
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002173483 | 2002-06-14 | ||
EP03760132A EP1514542B1 (en) | 2002-06-14 | 2003-04-03 | Medicinal composition comprising Tacrine or Donepezil for improving brain function. |
PCT/JP2003/004292 WO2003105830A1 (ja) | 2002-06-14 | 2003-04-03 | 脳機能を改善する医薬組成物および脳機能を改善するための方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1120591T1 true CY1120591T1 (el) | 2019-12-11 |
Family
ID=29727916
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100432T CY1112958T1 (el) | 2002-06-14 | 2012-05-08 | Ιατρικες συνθεσεις που περιλαμβανουν τακρινη ή ντονεπεζιλη για βελτιωση εγκεφαλικης λειτουργιας |
CY181100871T CY1120591T1 (el) | 2002-06-14 | 2018-08-21 | Ιατρικη συνθεση για βελτιωση λειτουργιας εγκεφαλου |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100432T CY1112958T1 (el) | 2002-06-14 | 2012-05-08 | Ιατρικες συνθεσεις που περιλαμβανουν τακρινη ή ντονεπεζιλη για βελτιωση εγκεφαλικης λειτουργιας |
Country Status (23)
Country | Link |
---|---|
US (3) | USRE42327E1 (el) |
EP (2) | EP1514542B1 (el) |
JP (1) | JP4675103B2 (el) |
KR (1) | KR100935615B1 (el) |
CN (1) | CN100375619C (el) |
AT (1) | ATE546140T1 (el) |
AU (1) | AU2003236364C1 (el) |
BR (1) | BRPI0311780B8 (el) |
CA (1) | CA2488120C (el) |
CY (2) | CY1112958T1 (el) |
DK (2) | DK2389937T3 (el) |
ES (2) | ES2685923T3 (el) |
HU (1) | HUE041842T2 (el) |
IL (1) | IL165589A (el) |
MX (1) | MXPA04012534A (el) |
NO (1) | NO333504B1 (el) |
NZ (1) | NZ537090A (el) |
PL (1) | PL217394B1 (el) |
PT (2) | PT1514542E (el) |
SI (2) | SI1514542T1 (el) |
TR (1) | TR201816386T4 (el) |
WO (1) | WO2003105830A1 (el) |
ZA (1) | ZA200409901B (el) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1437353T3 (da) * | 2001-10-19 | 2007-08-06 | Toyama Chemical Co Ltd | Alkyletherderivater eller deres salte |
DK2389937T3 (en) | 2002-06-14 | 2018-11-12 | Toyama Chemical Co Ltd | Medical composition to improve brain function |
US20060205709A1 (en) * | 2003-04-17 | 2006-09-14 | Toyama Chemical Co., Ltd. | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof |
US7435837B2 (en) | 2003-10-24 | 2008-10-14 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
EP2258359A3 (en) * | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
US20090093453A1 (en) * | 2006-04-26 | 2009-04-09 | Toyama Chemical Co., Ltd | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
US8119625B2 (en) * | 2006-04-26 | 2012-02-21 | Toyama Chemical Co., Ltd. | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
DK2048145T3 (da) * | 2006-08-04 | 2011-04-04 | Toyama Chemical Co Ltd | Forstærker af aktiviteten af proteinkinase C indeholdende alkyletherderivat eller et salt deraf |
US20090221554A1 (en) * | 2008-02-28 | 2009-09-03 | Zenyaku Kogyo Kabushiki Kaisha | Method of treating cognitive impairment |
MX2010012787A (es) * | 2008-05-28 | 2011-02-24 | Toyama Chemical Co Ltd | Nuevo derivado de oxido de benzotiofeno y sal del mismo. |
US10017445B2 (en) | 2012-07-12 | 2018-07-10 | Concert Pharmaceuticals, Inc. | Deuterated idebenone |
CN106061478B (zh) | 2014-01-31 | 2019-04-30 | 富士胶片富山化学株式会社 | 含有烷基醚衍生物或其盐的神经损伤后的康复效果促进剂 |
AU2018277982B2 (en) | 2017-06-02 | 2021-04-08 | Fujifilm Toyama Chemical Co., Ltd. | Agent for preventing or treating tauopathy |
SG11201911519UA (en) | 2017-06-02 | 2020-01-30 | Fujifilm Toyama Chemical Co Ltd | AGENT FOR REDUCING AMOUNT OF AMYLOID ß PROTEIN |
JP7282028B2 (ja) | 2017-06-02 | 2023-05-26 | 富士フイルム富山化学株式会社 | 脳萎縮予防または治療剤 |
JPWO2018221728A1 (ja) * | 2017-06-02 | 2020-04-02 | 富士フイルム富山化学株式会社 | アルツハイマー型認知症予防または治療剤 |
US11660287B2 (en) | 2017-06-02 | 2023-05-30 | Fujifilm Toyama Chemical Co., Ltd. | Agent for preventing or treating spinocerebellar ataxia |
KR20200024854A (ko) * | 2017-07-08 | 2020-03-09 | 더 제너럴 하스피탈 코포레이션 | 알츠하이머 질환의 치료를 위한 치료 약물 또는 제제를 확인하기 위한 스크리닝 플랫폼 |
US11548878B2 (en) | 2017-10-30 | 2023-01-10 | Fujifilm Toyama Chemical Co., Ltd. | Emopamil binding protein binding agent and use thereof |
CN110464834B (zh) * | 2019-09-04 | 2022-12-02 | 北京豪思生物科技股份有限公司 | 铜蓝蛋白联合多奈哌齐的应用 |
KR20220040294A (ko) | 2020-09-23 | 2022-03-30 | 씨엔지바이오 주식회사 | 6-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물 |
KR20220040291A (ko) | 2020-09-23 | 2022-03-30 | 씨엔지바이오 주식회사 | 4-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL74497A (en) | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
US5177082A (en) | 1985-11-05 | 1993-01-05 | Yu Chao Mei | Huperzines and analogs |
US4663318A (en) | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
JPH0210827A (ja) | 1988-06-29 | 1990-01-16 | Matsushita Electron Corp | 半導体装置の製造方法 |
US5280032A (en) | 1989-02-14 | 1994-01-18 | Toyama Chemical Co., Ltd. | 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same |
JP2887492B2 (ja) * | 1990-02-05 | 1999-04-26 | 富山化学工業株式会社 | 1,2―エタンジオール誘導体およびその塩 |
NZ232493A (en) * | 1989-02-14 | 1992-06-25 | Toyama Chemical Co Ltd | Aryl- or heterocyclyl-substituted 1,2-ethanediol derivatives and pharmaceutical compositions |
JP2913196B2 (ja) | 1989-04-26 | 1999-06-28 | 富山化学工業株式会社 | 1,2−エタンジオール誘導体またはその塩 |
US4914102A (en) * | 1989-09-28 | 1990-04-03 | Hoechst Roussel Pharmaceuticals, Inc. | N-aminocarbamates related to physostigmine, pharmacentical compositions and use |
JP3044055B2 (ja) | 1990-08-09 | 2000-05-22 | 富山化学工業株式会社 | 1,2―エタンジオール誘導体およびその塩 |
JPH0676401B2 (ja) | 1990-10-19 | 1994-09-28 | エスエス製薬株式会社 | キノリン誘導体及びこれを含有する医薬 |
TW197435B (el) | 1990-11-22 | 1993-01-01 | Takeda Pharm Industry Co Ltd | |
DE4111861A1 (de) | 1991-04-11 | 1992-10-15 | Schwabe Willmar Gmbh & Co | Benzopyranone, verfahren zu ihrer herstellung und verwendung |
JP2925363B2 (ja) | 1991-07-09 | 1999-07-28 | キヤノン株式会社 | 画像処理方法及び装置 |
DE4136288A1 (de) * | 1991-11-04 | 1993-05-06 | Troponwerke Gmbh & Co Kg, 5000 Koeln, De | Kombination von calciumantagonisten mit cholinesterase-inhibitoren |
JP3232830B2 (ja) | 1993-11-30 | 2001-11-26 | 三菱電機株式会社 | フレキシブルディスク装置のキャリッジ機構 |
WO1996012717A1 (fr) | 1994-10-25 | 1996-05-02 | Toyama Chemical Co., Ltd. | Potentialisateur de l'activite du facteur de croissance nerveuse contenant un derive de 1,2-ethanediol ou un sel de celui-ci |
IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
US5889006A (en) | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
AU1672597A (en) * | 1996-02-20 | 1997-09-10 | Toyama Chemical Co. Ltd. | Cerebral function ameliorant containing 1,2-ethanediol derivatives or salts thereof |
HUP9904622A3 (en) * | 1996-07-10 | 2001-07-30 | Schering Corp | 1,4-di-sustituted piperidines as muscarinic antagonists |
KR20000029976A (ko) | 1996-08-15 | 2000-05-25 | 둘락 노먼 씨. | 에테르무스카린성길항제 |
JPH10259126A (ja) | 1997-01-17 | 1998-09-29 | Takeda Chem Ind Ltd | アルツハイマー病治療・予防剤 |
US20030092737A1 (en) | 1997-11-14 | 2003-05-15 | Pierre Maffrand Jean | Combination of active ingredients for the treatment of senile dementia of the Alzheimer type |
CO4980891A1 (es) * | 1997-11-14 | 2000-11-27 | Sanofi Sa | Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer |
WO1999031056A1 (fr) | 1997-12-12 | 1999-06-24 | Toyama Chemical Co., Ltd. | Derives d'ether alcoylique ou leurs sels, et antagonistes du calcium les contenant |
KR100641352B1 (ko) | 1999-06-11 | 2006-11-02 | 토야마 케미칼 컴퍼니 리미티드 | N-알콕시알킬-n,n-디알킬아민 유도체 또는 그 염, 및이를 함유하는 신경퇴행성질환 치료제 |
DK1437353T3 (da) | 2001-10-19 | 2007-08-06 | Toyama Chemical Co Ltd | Alkyletherderivater eller deres salte |
DK2389937T3 (en) | 2002-06-14 | 2018-11-12 | Toyama Chemical Co Ltd | Medical composition to improve brain function |
US20060205709A1 (en) | 2003-04-17 | 2006-09-14 | Toyama Chemical Co., Ltd. | Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof |
US20090093453A1 (en) | 2006-04-26 | 2009-04-09 | Toyama Chemical Co., Ltd | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
US8119625B2 (en) | 2006-04-26 | 2012-02-21 | Toyama Chemical Co., Ltd. | Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
-
2003
- 2003-04-03 DK DK11006318.7T patent/DK2389937T3/en active
- 2003-04-03 KR KR1020047020053A patent/KR100935615B1/ko active IP Right Grant
- 2003-04-03 US US12/683,813 patent/USRE42327E1/en not_active Expired - Lifetime
- 2003-04-03 ES ES11006318.7T patent/ES2685923T3/es not_active Expired - Lifetime
- 2003-04-03 BR BRPI0311780A patent/BRPI0311780B8/pt not_active IP Right Cessation
- 2003-04-03 CA CA2488120A patent/CA2488120C/en not_active Expired - Lifetime
- 2003-04-03 AU AU2003236364A patent/AU2003236364C1/en not_active Expired
- 2003-04-03 AT AT03760132T patent/ATE546140T1/de active
- 2003-04-03 WO PCT/JP2003/004292 patent/WO2003105830A1/ja active Application Filing
- 2003-04-03 PL PL372934A patent/PL217394B1/pl unknown
- 2003-04-03 EP EP03760132A patent/EP1514542B1/en not_active Expired - Lifetime
- 2003-04-03 DK DK03760132.5T patent/DK1514542T3/da active
- 2003-04-03 MX MXPA04012534A patent/MXPA04012534A/es active IP Right Grant
- 2003-04-03 SI SI200332141T patent/SI1514542T1/sl unknown
- 2003-04-03 PT PT03760132T patent/PT1514542E/pt unknown
- 2003-04-03 IL IL165589A patent/IL165589A/en active IP Right Grant
- 2003-04-03 CN CNB038138573A patent/CN100375619C/zh not_active Expired - Lifetime
- 2003-04-03 EP EP11006318.7A patent/EP2389937B1/en not_active Expired - Lifetime
- 2003-04-03 JP JP2004512734A patent/JP4675103B2/ja not_active Expired - Lifetime
- 2003-04-03 HU HUE11006318A patent/HUE041842T2/hu unknown
- 2003-04-03 TR TR2018/16386T patent/TR201816386T4/tr unknown
- 2003-04-03 SI SI200332578T patent/SI2389937T1/sl unknown
- 2003-04-03 US US10/516,320 patent/US7342043B2/en not_active Ceased
- 2003-04-03 ES ES03760132T patent/ES2379948T3/es not_active Expired - Lifetime
- 2003-04-03 PT PT11006318T patent/PT2389937T/pt unknown
- 2003-04-03 NZ NZ537090A patent/NZ537090A/en not_active IP Right Cessation
-
2004
- 2004-11-25 NO NO20045158A patent/NO333504B1/no not_active IP Right Cessation
- 2004-12-07 ZA ZA200409901A patent/ZA200409901B/xx unknown
-
2007
- 2007-12-17 US US11/957,832 patent/US7834053B2/en not_active Expired - Lifetime
-
2012
- 2012-05-08 CY CY20121100432T patent/CY1112958T1/el unknown
-
2018
- 2018-08-21 CY CY181100871T patent/CY1120591T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120591T1 (el) | Ιατρικη συνθεση για βελτιωση λειτουργιας εγκεφαλου | |
PT1259489E (pt) | Compostos azapoliciclicos condensados con arilo. | |
UA83899C2 (uk) | Сполуки імідазолу для лікування нейродегенеративних розладів | |
TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
CA2501799A1 (en) | Pyrazole compounds for treatment of neurodegenerative disorders | |
CA2534532A1 (en) | Compounds for the treatment of neurodegenerative disorders | |
MY136718A (en) | Sulfonamide compounds for the treatment of neurodegenerative disorders | |
MXPA05012196A (es) | Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos. | |
DE69033369D1 (de) | 1,2,3,4-Tetrahydro-9-Akridinamine-Derivate | |
WO2005095348A3 (en) | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | |
WO2005097114A3 (en) | Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders | |
WO2007034326A3 (en) | Imidazole compounds for the treatment of neurological disorders | |
DE69822937D1 (de) | Indolmorphinan-derivate und medikamente zur behandlung/mittel zur vorbeugung von cerebralen störungen | |
ATE421961T1 (de) | Piperidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung zur behandlung von alzheimer-krankheit, die diese derivate enthält | |
NO891071D0 (no) | Fremgangsmaate for fremstilling av 4,5,6,7-tetrahydro-isotiazolo(4,5-c)-pyridinderivater og isomere. | |
WO2005095361A8 (en) | Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders | |
ATE248172T1 (de) | Heterocyclische verbindungen und ihre herstellung und verwendung | |
DE602005012826D1 (de) | Neue mao-b-hemmer |